Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
about
GARP: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasingHigh expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T CellsDifferential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4.LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escapeLymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral loadLAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors.Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responsesCharacterization and functional studies of forkhead box protein 3(-) lymphocyte activation gene 3(+) CD4(+) regulatory T cells induced by mucosal B cells.PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in miceLAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.Mixing Signals: Molecular Turn Ons and Turn Offs for Innate γδ T-Cells.Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cellsLAG-3 regulates plasmacytoid dendritic cell homeostasisCD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells.Lymphocyte Activation Gene-3 (LAG-3) negatively regulates environmentally-induced autoimmunity.Metalloproteases regulate T-cell proliferation and effector function via LAG-3High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies.Inhibitory receptors as targets for cancer immunotherapyModulation of redox balance leaves murine diabetogenic TH1 T cells "LAG-3-ing" behind.Encounter with antigen-specific primed CD4 T cells promotes MHC class II degradation in dendritic cellsUsing histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance.Costimulatory and coinhibitory receptors in anti-tumor immunityGenetic and biochemical regulation of CD4 T cell effector differentiation: insights from examination of T cell clonal anergy.The CD4-like molecule LAG-3, biology and therapeutic applications.Immune evasion in acute myeloid leukemia: current concepts and future directions.Immunological landscape and immunotherapy of hepatocellular carcinoma.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.LAG3 (CD223) as a cancer immunotherapy target.Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses.Suppression of CD4+ Effector Responses by Naturally Occurring CD4+ CD25+ Foxp3+ Regulatory T Cells Contributes to Experimental Cerebral Malaria.Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.Layers of regulation in induction of mixed chimerism by anti-CD40L.
P2860
Q26752197-21FBC542-D325-4742-9570-657CA38E84CFQ33813862-BB572430-544E-49A5-9AFC-52F19AEF9EC8Q33900380-1697D03D-FFF1-45DC-838A-5D78801DFF24Q34110093-B13486E7-CB32-4459-80E9-6525B291FF19Q34172252-440CA6AE-A502-4669-A72C-959612BBA1EAQ34211374-D24BE468-FBB7-4297-BA16-74552E4B73F1Q34241893-EE7D5495-5FC0-4751-B58C-59848901E1EAQ34381879-40698941-E7B5-407E-BB8D-1925DCE043BCQ34395893-1ECF6F54-AA02-49EA-B354-C9E0FE1E3133Q34451999-B1AEF1C1-EC9E-44BF-A22E-217A327EDF18Q34457788-4C37BB67-5BCA-428F-8014-63D40117DB34Q34577678-97844486-EE60-4F90-B2E5-7973AB2F4E60Q34700552-9AC0C272-F591-4CE6-B4A9-A56750C6B1D8Q34730063-427969F6-1967-4EE0-88CC-10406DBA5E89Q34856800-8DD1C2C3-93D9-45E3-A3B6-94B390FB0740Q34939924-F01D535D-963B-4B9B-B2CA-D61F5F019F44Q34996431-1441ECCA-666C-46BB-A781-EA1C842A7483Q35186239-DBD4C4D9-3441-47E7-B3DB-F9D212E97125Q35224733-E5C61342-C477-4517-BE0A-F262F49DEFE9Q35612460-429FC093-7065-4FE1-AEC9-04499C81EF2EQ35826509-1E3B5E3A-015E-4B84-8033-4EC1A4A471D6Q35954596-87CAA2BE-E987-4768-8D2B-0F2CA657C513Q35995373-ED1C65C9-0A07-4128-99D9-5155243B5B26Q36047584-2932B3CE-0F67-4318-AD63-1D021CBD29F9Q36436748-F23DBF7F-A87D-4FDB-B0CC-75DE58D0A495Q37378417-06862E27-C7B5-4D3E-988F-197D608BCFACQ37474920-FD2FF259-D3CC-4B76-A2F3-9D297B54FDDCQ37676041-9817E9F7-13B9-4524-8155-2F47313B57D2Q37818246-C76A6BCE-1E52-4429-9492-CF29057AA4C0Q38172521-D0720CC9-6C99-440C-A3A8-203EAABFF256Q38611895-CA473D64-924C-4EC4-ACC3-10295A87A93DQ38666253-8B7A52FC-3EF1-498C-9AAE-06737BFB1EBCQ38838178-B4ED7DDD-429A-41A9-8149-A607C92BBC7FQ39160974-F5001F26-6B2B-4DCE-BEBD-C3F59606490FQ39181825-B6D259A6-26AB-4DDC-8CB4-363D70FE7604Q39308337-36B781A9-F37F-49E7-937A-0AEEA66DD6C9Q39748865-778E46A6-B206-48C0-8035-E9C1CAD1D042Q40916203-C49B80E0-060B-477E-AC61-6FBC37455B27Q41015843-31D552A6-A06E-4F72-9F1D-96FF1C1C8CA6Q42083190-067CFE10-A49D-4109-ADC0-6585E522744D
P2860
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@ast
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@en
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@nl
type
label
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@ast
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@en
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@nl
prefLabel
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@ast
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@en
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@nl
P2093
P1476
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
@en
P2093
Cornelia Kurschner
Creg J Workman
Dario A A Vignali
Dennis S Rice
Kari J Dugger
P304
P356
10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A
P407
P577
2002-08-01T00:00:00Z